Primary Biliary Cholangitis Treatment: What Works in 2026

Primary Biliary Cholangitis (PBC) isn't something most people hear about until it affects them or someone they love. It’s a quiet disease - no fever, no sudden pain - just a slow, steady damage to the tiny bile ducts inside the liver. Over time, bile builds up, scarring sets in, and the liver struggles to function. It mostly hits women between 30 and 65, and while we don’t know exactly why, genetics and environmental triggers like certain infections play a role. The good news? We have better tools than ever to stop it in its tracks - if you know what they are.

First-Line Treatment: Ursodeoxycholic Acid (UDCA)

For over 30 years, Ursodeoxycholic acid (a naturally occurring bile acid used to treat PBC by reducing toxic bile buildup and calming immune activity in the liver) has been the foundation of PBC care. Taken daily at a dose of 13-15 mg per kilogram of body weight, it works by replacing harmful bile acids with ones the liver can handle better. It also helps the liver flush out toxins and reduces inflammation.

It’s not perfect - about 35% of patients don’t respond well. But for the rest, it’s life-changing. Studies show that people who respond to UDCA have an 87% chance of living 10 years without needing a transplant. Those who don’t respond? Only 69%. That gap is huge. That’s why checking your liver enzyme levels - especially alkaline phosphatase (ALP) - every 3 to 6 months is non-negotiable. If your ALP stays above 1.67 times the normal limit after a year of UDCA, it’s time to talk about next steps.

The New Second-Line Options: Seladelpar and Elafibranor

Until late 2024, the only real option after UDCA failed was obeticholic acid (Ocaliva). But in September 2025, the FDA pulled it off the market. Why? Too many patients had severe itching, and some faced higher risks of heart problems and liver failure, especially if they already had advanced scarring.

Now, two new drugs have taken its place - and they’re changing the game.

Seladelpar (a selective PPAR-delta agonist approved in December 2024, marketed as Livdelzi by Gilead Sciences) is now the go-to second-line treatment. Taken once daily, starting at 5 mg and increasing to 10 mg after four weeks, it targets the root of liver inflammation. In clinical trials, 70% of patients saw their ALP drop by at least 15%, and 42% got it back to normal levels - nearly seven times better than placebo. What’s more, it significantly reduces itching - a major problem for 7 out of 10 PBC patients. In one trial, itching scores dropped by 45% compared to just 15% with placebo. That’s not just a number - it’s better sleep, less scratching, and the ability to focus on life again.

There’s a catch: about 25% of people feel more itching in the first two weeks. But here’s the good part - in 92% of those cases, it fades by week eight. Doctors now know to prepare patients for this bump, not panic. Real-world data from over 390 patients shows that 85% stick with seladelpar after a year.

Elafibranor (a dual PPAR-alpha/delta agonist approved in November 2024, marketed as Iqirvo by Genfit) is the other option. Taken as one 80 mg pill daily, it’s simpler - no titration needed. It’s slightly less powerful at lowering ALP (56% achieve meaningful reduction, 21% reach normal levels) but better for patients with high triglycerides - it lowers them by 24%, while seladelpar only drops them by 8%. It also helps with itching, cutting scores by 38%. But it can raise creatinine levels in 18% of users, meaning kidney function needs monitoring.

How the Two New Drugs Compare

Choosing between seladelpar and elafibranor depends on your symptoms and health profile.

For most patients with intense itching and high ALP, seladelpar is the better choice. If you’re also dealing with high cholesterol or triglycerides and don’t have severe itching, elafibranor might be a solid fit. Either way, both are better than the old option - and both are backed by real data from thousands of patients.

What About Fibrates and Other Options?

Before the new drugs came along, doctors sometimes used fibrates - medications like fenofibrate or bezafibrate - off-label for PBC. These are typically used for cholesterol, but they also reduce ALP and improve liver enzymes. Some studies show they help when UDCA alone isn’t enough. They’re cheaper and available as generics, but they’re not FDA-approved for PBC. That means insurance might not cover them, and long-term safety data is thinner.

Right now, experts recommend fibrates only if the newer drugs aren’t accessible - either because of cost or availability. But research is ongoing. Drugs like setanaxib (targeting oxidative stress) and VE-202 (a gut microbiome therapy) are in trials. One of them might be next.

Monitoring and Real-World Outcomes

It’s not enough to just take the medicine. You need to track progress. ALP levels shouldn’t be checked once and forgotten. They need to be followed every 3 months during the first year, then every 6 months. A single high number doesn’t mean treatment failed - trends do. If your ALP drops by 15% and stays down, even if it’s not perfectly normal, you’re still gaining protection.

Real-world data from Johns Hopkins and other centers shows patients switching from Ocaliva to seladelpar often feel better within 8 weeks. Quality of life improves. Fatigue lifts. Sleep returns. That’s not just science - it’s lived experience.

But access is still a hurdle. Medicare requires proof of UDCA failure and ALP >1.67x normal before approving seladelpar or elafibranor. And even then, 28% of prior authorization requests get denied. That’s why working with a hepatologist who knows the system matters. Many academic centers have streamlined this process. Community clinics? Not always.

The Future: More Than Just ALP

The field is shifting. We’re no longer just chasing enzyme numbers. The FDA just approved a new tool called PBC-40 PRO - a patient-reported survey that measures itching, fatigue, and quality of life. In the next 5 years, trials will need to prove they improve how patients feel, not just what labs show.

And affordability? That’s the next battle. Right now, 40% of insured patients pay over $500 a month out of pocket for these new drugs. That’s unsustainable. Advocacy groups are pushing for value-based pricing. Until then, patients need to know: help is out there - from nonprofit support programs to manufacturer assistance apps like the PBC Foundation’s Treatment Navigator.

There’s no cure yet. But we’ve gone from watching the disease creep forward to having real tools to stop it. The key is knowing what’s available, staying on top of your numbers, and not giving up if the first drug doesn’t work. PBC is slow - but so are the answers. And now, they’re working.